Daewoong Pharmaceutical Co. LTD.
daewoong.co.krLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
197
Active
27
Phase 3
50
Total enrollment
184,424
Pipeline matrix
Showing 36 of 36 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Lansoprazole 15 mg | — | — | — | — | 3 | ||
| Lansoprazole 15 mg placebo | — | — | — | — | 3 | ||
| Fexuprazan 20mg | — | — | — | — | — | 1 | |
| Fexuprazan 20mg placebo | — | — | — | — | — | 1 | |
| DWP16001 0.3mg | — | — | — | — | 3 | ||
| DWP16001 | — | — | — | 17 | |||
| DWP16001 Placebo | — | — | — | — | — | 3 | |
| DWP712 inj. | — | — | — | — | — | 1 | |
| Botox® 100 Units | — | — | — | — | — | 1 | |
| DWC202518 | — | — | — | — | — | 1 | |
| DWN12088 | — | — | — | — | 3 | ||
| DWC202313, DWC202314 | — | — | — | — | 3 | ||
| DWJ1622 | — | — | — | — | — | 2 | |
| DWP212525 XXmg | — | — | — | — | — | 1 | |
| DWP212525 placebo | — | — | — | — | — | 1 | |
| DWRX5003 | — | — | — | — | — | 1 | |
| DWC202502 | — | — | — | — | — | 1 | |
| DWC202503 | — | — | — | — | — | 1 | |
| Period 1 | — | — | — | — | — | 1 | |
| Period 2 | — | — | — | — | — | 1 | |
| Period 3 | — | — | — | — | — | 1 | |
| Period 4 | — | — | — | — | — | 1 | |
| DWC202407 1,000mg | — | — | — | — | — | 1 | |
| DWC202408 2mg | — | — | — | — | — | 1 | |
| DWJ1511 | — | — | — | — | — | 1 | |
| DWC202501 | — | — | — | — | — | 1 | |
| DWZ2501 | — | — | — | — | — | 1 | |
| DWC202510 | — | — | — | — | — | 1 | |
| Envlo | — | — | — | — | — | 2 | |
| Statin+Ezetimibe compound | — | — | — | — | — | 1 | |
| Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca | — | — | — | — | — | 1 | |
| Ezetimibe/Rosuvastatin | — | — | — | — | — | 1 | |
| Envolomet SR | — | — | — | — | — | 1 | |
| Rosuvastatin, Olmesartan Medoxomil | — | — | — | — | — | 1 | |
| Envlomet SR | — | — | — | — | — | 1 | |
| Enavogliflozin | — | — | — | — | — | 1 |
Next readouts
- 2023-12-31
- 2024-11-30
- 2024-12-03
- 2024-12-31
- 2025-01
- 2025-01-17
- 2025-03-31
- 2025-09
- 2025-12-31
- 2025-12-31
Top conditions
- Healthy53
- Healthy Volunteers13
- Hypertension9
- T2DM (Type 2 Diabetes Mellitus)8
- Dyslipidemias6
- Dyslipidemia5
- Diabetes Mellitus, Type 25
- Drug Drug Interaction4
Frequently asked questions about Daewoong Pharmaceutical Co. LTD.
- How many clinical trials does Daewoong Pharmaceutical Co. LTD. have on ClinicalTrials.gov?
- Daewoong Pharmaceutical Co. LTD. is listed as the lead sponsor on 197 clinical trials in ClinicalTrials.gov, 27 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Daewoong Pharmaceutical Co. LTD.'s trials are in Phase 3?
- 50 of Daewoong Pharmaceutical Co. LTD.'s trials are in Phase 3, spread across 36 active drug programs.
- What therapeutic areas does Daewoong Pharmaceutical Co. LTD. focus on?
- Daewoong Pharmaceutical Co. LTD.'s most-studied conditions on ClinicalTrials.gov are Healthy, Healthy Volunteers, Hypertension, T2DM (Type 2 Diabetes Mellitus), Dyslipidemias.
- When are Daewoong Pharmaceutical Co. LTD.'s next clinical trial readouts?
- Daewoong Pharmaceutical Co. LTD. has 10 upcoming primary-completion readouts tracked here; the soonest is “Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment”, expected around 2023-12-31.